Health
Johnson & Johnson COVID-19 vaccine candidate enters late-stage trials | News – Daily Hive
One shot, instead of two.
Pharma giant Johnson & Johnson has announced its COVID-19 vaccine candidate has entered the late-stage trials.
The pharmaceutical company said about 45,000 participants are currently enrolled in the trials, with interim data expected by the end of January 2021.
If the Johnson & Johnson vaccine candidate proves effective, the company says it will submit an emergency use authorization application to the US Food and Drug Administration (FDA) in February.
Johnson & Johnson’s study, named Ensemble, was…
-
Business21 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business20 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Noosa News17 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business17 hours ago1 ASX dividend stock down 43% I’d buy right now